Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 3
Submit an article Journal homepage
3,721
Views
8
CrossRef citations to date
0
Altmetric
Neurology

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

Patrick Vermerscha Inserm U1172, CHU Lille, FHU Imminent, University of Lille, Lille, France
,
Andrew Galazkab Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
,
Fernando Dangondc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany
,
Doris Damianc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany
,
Schiffon L. Wongc EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany
,
Dominic Jackd Merck KGaA, Darmstadt, Germany
&
Gerard Hartyd Merck KGaA, Darmstadt, GermanyCorrespondence[email protected]
 show all
Pages 459-464 | Received 12 Nov 2020, Accepted 15 Dec 2020, Published online: 01 Feb 2021

References

  • Spelman T, Freilich J, Anell B, et al. Patients with high-disease-activity relapsing–remitting multiple sclerosis in real-world clinical practice: a population-based study in Sweden. Clin Ther. 2020;42(2):240–250.
  • Huisman E, Papadimitropoulou K, Jarrett J, et al. Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017;7(3):e013430.
  • Enzinger C, Fuchs S, Pichler A, et al. Predicting the severity of relapsing–remitting MS: the contribution of cross-sectional and short-term follow-up MRI data. Mult Scler. 2011;17(6):695–701.
  • Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846.
  • Farber RS, Sand IK. Optimizing the initial choice and timing of therapy in relapsing–remitting multiple sclerosis. Ther Adv Neurol Disord. 2015;8(5):212–232.
  • Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5–S48.
  • Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. JMCP. 2017;23(8):844–852.
  • Fernandez O. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75–83.
  • eMC. Mavenclad 10mg tablets [Internet]. London (UK): EMC; 2017 [cited 2017 Dec 18]. Available from: https://www.medicines.org.uk/emc/medicine/34044
  • Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426.
  • Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–337.
  • Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25(6):819–827.
  • Siddiqui MK, Khurana IS, Budhia S, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361–1371.
  • Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–846.
  • Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998;6(2):65–74.
  • Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572.
  • Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013;73(1):95–103.
  • Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545–559.
  • Mowry EM. Natural history of multiple sclerosis: early prognostic factors. Neurol Clin. 2011;29(2):279–292.
  • Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol Ther. 2019;8(1):13–23.
  • Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Amsterdam (The Netherlands): European Medicine Agency; 2015.
  • Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study. Neurology. 2016;86(16 Supplement):P3.028.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.